Features of the metabolic syndrome relating to cardiorenal outcomes

Archives of Medical Science

Volumn 4, Issue 4, 2008, Pages 424-426

  Kostapanos, Michael S ^a   Liamis, George L ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALBUMIN; ATORVASTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; URIC ACID;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; EDITORIAL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PREDICTION; RISK FACTOR; TREATMENT OUTCOME;

EID: 60249096968     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Zipes DP, Camm J, Borggrefe M, et al. ACC/AHA/ESC Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death executive summary. Circulation 2006; 114: 1088-132.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266.
3. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007; 82: 1381-90.
4. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
5. Manley HJ. Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management. J Manag Care Pharm 2007; 13 (9 Suppl D): S6-12.
6. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
7. Gazi I, Liberopoulos EN, Mikhailidis DP, Elisaf M. Metabolic syndrome: Clinical features leading to therapeutic strategies. Vasc Dis Prev 2004; 1: 243-53.
8. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 2004; 15: 2775-91.
9. Barylski M, Banach M, Mikhailidis DP, Pawlicki L, Kowalski J. Decreased kidney function as a risk factor for cardiovascular events in subjects with metabolic syndrome - a pilot study. Arch Med Sci 2008; 4: 417-23.
10. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
11. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958-73.
12. Filippatos TD, Tsimihodimos V, Kostapanos M, et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 2007; 3: 344-50.
13. Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
14. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301.
15. Liu SW, Qiao SB, Yuan JS, Liu DQ. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res 2008; in press.
16. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2094-9.
17. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-2.
18. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 203-9.
19. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. PAF-acetylhyrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant 2006; 21: 1270-7.
20. Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-65.
21. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-80.
22. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-43.
23. Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 578: 249-52.